Celldex Therapeutics, Inc. announced that an abstract describing the Phase 1b study of barzolvolimab in patients with prurigo nodularis (PN) has been accepted as an oral presentation at the 12th World Congress on Itch (WCI), being held in Miami on Nov. 5-7, 2023. The Phase 1b multi-center, randomized, double-blind, placebo-controlled trial is designed to study barzolvolimabin patients with prurigo nodularityis (PN), a chronic skin disease characterized by the development of hard, intensely itchy (pruritic) nodules on the skin.